NASDAQ:TYME

Tyme Technologies (TYME) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.29
$0.32
50-Day Range
$0.24
$0.35
52-Week Range
$0.22
$1.14
Volume
2.68 million shs
Average Volume
1.01 million shs
Market Capitalization
$53.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TYME stock logo

About Tyme Technologies Stock (NASDAQ:TYME)

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

TYME Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Ninja Foodi Beef Stew
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Eden Green Launches Flagship Herb Program
Clos Apalta: fabulous wines from Chile
The 8 Best New Colognes of 2024 (So Far)
Women's Health
Ninja Foodi Lamb Chops
How to use essential oils
See More Headlines
Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
4/23/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TYME
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

Net Income
$-23,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.47 per share

Miscellaneous

Free Float
143,104,000
Market Cap
$53.50 million
Optionable
Optionable
Beta
0.93
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


TYME Stock Analysis - Frequently Asked Questions

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) issued its earnings results on Monday, November, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03.

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

This page (NASDAQ:TYME) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners